Cargando…

Imipramine blocks acute silicosis in a mouse model

BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotro...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Rupa, Trout, Kevin L., Jessop, Forrest, Harkema, Jack R., Holian, Andrij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594487/
https://www.ncbi.nlm.nih.gov/pubmed/28893276
http://dx.doi.org/10.1186/s12989-017-0217-1
_version_ 1783263212285722624
author Biswas, Rupa
Trout, Kevin L.
Jessop, Forrest
Harkema, Jack R.
Holian, Andrij
author_facet Biswas, Rupa
Trout, Kevin L.
Jessop, Forrest
Harkema, Jack R.
Holian, Andrij
author_sort Biswas, Rupa
collection PubMed
description BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics. The aim of this study was to evaluate the potential for IMP to reduce silicosis and block phagolysosome membrane permeabilization. METHODS: C57BL/6 alveolar macrophages (AM) exposed to crystalline silica ± IMP in vitro were assessed for IL-1β release, cytotoxicity, particle uptake, lysosomal stability, and acid sphingomyelinase activity. Short term (24 h) in vivo studies in mice instilled with silica (± IMP) evaluated inflammation and cytokine release, in addition to cytokine release from ex vivo cultured AM. Long term (six to ten weeks) in vivo studies in mice instilled with silica (± IMP) evaluated histopathology, lung damage, and hydroxyproline content as an indicator of collagen accumulation. RESULTS: IMP significantly attenuated silica-induced cytotoxicity and release of mature IL-1β from AM in vitro. IMP treatment in vivo reduced silica-induced inflammation in a short-term model. Furthermore, IMP was effective in blocking silica-induced lung damage and collagen deposition in a long-term model. The mechanism by which IMP reduces inflammation was explored by assessing cellular processes such as particle uptake and acid sphingomyelinase activity. CONCLUSIONS: Taken together, IMP was anti-inflammatory against silica exposure in vitro and in vivo. The results were consistent with IMP blocking silica-induced phagolysosomal lysis, thereby preventing cell death and IL-1β release. Thus, IMP could be therapeutic for silica-induced inflammation and subsequent disease progression as well as other diseases involving phagolysosomal lysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12989-017-0217-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5594487
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55944872017-09-14 Imipramine blocks acute silicosis in a mouse model Biswas, Rupa Trout, Kevin L. Jessop, Forrest Harkema, Jack R. Holian, Andrij Part Fibre Toxicol Research BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics. The aim of this study was to evaluate the potential for IMP to reduce silicosis and block phagolysosome membrane permeabilization. METHODS: C57BL/6 alveolar macrophages (AM) exposed to crystalline silica ± IMP in vitro were assessed for IL-1β release, cytotoxicity, particle uptake, lysosomal stability, and acid sphingomyelinase activity. Short term (24 h) in vivo studies in mice instilled with silica (± IMP) evaluated inflammation and cytokine release, in addition to cytokine release from ex vivo cultured AM. Long term (six to ten weeks) in vivo studies in mice instilled with silica (± IMP) evaluated histopathology, lung damage, and hydroxyproline content as an indicator of collagen accumulation. RESULTS: IMP significantly attenuated silica-induced cytotoxicity and release of mature IL-1β from AM in vitro. IMP treatment in vivo reduced silica-induced inflammation in a short-term model. Furthermore, IMP was effective in blocking silica-induced lung damage and collagen deposition in a long-term model. The mechanism by which IMP reduces inflammation was explored by assessing cellular processes such as particle uptake and acid sphingomyelinase activity. CONCLUSIONS: Taken together, IMP was anti-inflammatory against silica exposure in vitro and in vivo. The results were consistent with IMP blocking silica-induced phagolysosomal lysis, thereby preventing cell death and IL-1β release. Thus, IMP could be therapeutic for silica-induced inflammation and subsequent disease progression as well as other diseases involving phagolysosomal lysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12989-017-0217-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-11 /pmc/articles/PMC5594487/ /pubmed/28893276 http://dx.doi.org/10.1186/s12989-017-0217-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Biswas, Rupa
Trout, Kevin L.
Jessop, Forrest
Harkema, Jack R.
Holian, Andrij
Imipramine blocks acute silicosis in a mouse model
title Imipramine blocks acute silicosis in a mouse model
title_full Imipramine blocks acute silicosis in a mouse model
title_fullStr Imipramine blocks acute silicosis in a mouse model
title_full_unstemmed Imipramine blocks acute silicosis in a mouse model
title_short Imipramine blocks acute silicosis in a mouse model
title_sort imipramine blocks acute silicosis in a mouse model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594487/
https://www.ncbi.nlm.nih.gov/pubmed/28893276
http://dx.doi.org/10.1186/s12989-017-0217-1
work_keys_str_mv AT biswasrupa imipramineblocksacutesilicosisinamousemodel
AT troutkevinl imipramineblocksacutesilicosisinamousemodel
AT jessopforrest imipramineblocksacutesilicosisinamousemodel
AT harkemajackr imipramineblocksacutesilicosisinamousemodel
AT holianandrij imipramineblocksacutesilicosisinamousemodel